Special Issue

Oropouche Virus (OROV): An Emerging Peribunyavirus (Bunyavirus)

Message from the Guest Editors

This Special Issue on *Viruses* will address topics addressing the Oropouche virus, including biological aspects such as virology, genetic variation, immunology, and host factors. Articles on the epidemiology of Oropouche fever are requested, including insect vectors and natural hosts, transmission dynamics, geographical distribution, natural history, and relationships with other related arboviruses. Clinical articles will discuss the presentation, diagnosis, treatment, prevention, and potential for vaccine and antiviral medication development. Experimental infections in animal models and cell culture are welcome. Articles discussing any aspect of the 2023-2024 OROV epidemic are welcomed, and, in particular, the occurrence of Oropouche fever in pregnancy and its association with obstetrical disease, fetal loss, vertical transmission, congenital microcephaly, and fetal malformations. Submissions can be original research articles, reviews, communications, viewpoints, case reports, and editorials. Illustrative and graphic materials, including photographs, are encouraged whenever possible.

Guest Editors

Dr. David A. Schwartz

Perinatal Pathology Consulting, Atlanta, GA, USA

Prof. Dr. André Ricardo Ribas Freitas

Department of Epidemiology, São Leopoldo Mandic Medical School, Campinas-SP, São Paulo 13045-755, Brazil

Deadline for manuscript submissions

1 June 2026



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/216348

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAq, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).